 Drug Approval
"Drug Approval" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Process that is gone through in order for a drug to receive approval by a government regulatory agency. This includes any required pre-clinical or clinical testing, review, submission, and evaluation of the applications and test results, and post-marketing surveillance of the drug.
| Descriptor ID |
D017277
|
| MeSH Number(s) |
E05.337.300 I01.880.604.605.250.250
|
| Concept/Terms |
Drug Approval- Drug Approval
- Approval, Drug
- Approvals, Drug
- Drug Approvals
- Food and Drug Administration Drug Approval
Drug Approval Process- Drug Approval Process
- Approval Process, Drug
- Approval Processes, Drug
- Drug Approval Processes
- Process, Drug Approval
- Processes, Drug Approval
New Drug Approval- New Drug Approval
- Approval, New Drug
- Approvals, New Drug
- Drug Approval, New
- Drug Approvals, New
- New Drug Approvals
|
Below are MeSH descriptors whose meaning is more general than "Drug Approval".
Below are MeSH descriptors whose meaning is more specific than "Drug Approval".
This graph shows the total number of publications written about "Drug Approval" by people in this website by year, and whether "Drug Approval" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 0 | 1 | | 2002 | 0 | 1 | 1 | | 2005 | 0 | 1 | 1 | | 2007 | 0 | 1 | 1 | | 2008 | 1 | 0 | 1 | | 2011 | 2 | 0 | 2 | | 2012 | 1 | 1 | 2 | | 2013 | 2 | 0 | 2 | | 2014 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Drug Approval" by people in Profiles.
-
Feely MA, Smith BL, Weinberg JM. Novel psoriasis therapies and patient outcomes, part 2: biologic treatments. Cutis. 2015 May; 95(5):282-90.
-
Briesacher BA, Soumerai SB, Zhang F, Toh S, Andrade SE, Wagner JL, Shoaibi A, Gurwitz JH. Response to the letter by Mol. Pharmacoepidemiol Drug Saf. 2014 Jan; 23(1):106.
-
Briesacher BA, Soumerai SB, Zhang F, Toh S, Andrade SE, Wagner JL, Shoaibi A, Gurwitz JH. A critical review of methods to evaluate the impact of FDA regulatory actions. Pharmacoepidemiol Drug Saf. 2013 Sep; 22(9):986-94.
-
Vital EM, Kay J, Emery P. Rituximab biosimilars. Expert Opin Biol Ther. 2013 Jul; 13(7):1049-62.
-
Kay J, Feagan BG, Guirguis MS, Keystone EC, Klein AV, Lubiniecki AS, Mould DR, Nyarko KA, Ridgway AA, Trudeau ME, Wang J. Health Canada/BIOTECanada Summit on regulatory and clinical topics related to subsequent entry biologics (biosimilars), Ottawa, Canada, 14 May 2012. Biologicals. 2012 Nov; 40(6):517-27.
-
Scheinberg MA, Kay J. The advent of biosimilar therapies in rheumatology--"O brave new world". Nat Rev Rheumatol. 2012 Jul; 8(7):430-6.
-
Irwin RS, Smith BS. Managing cough in the aftermath of the decision of the US Food and Drug Administration to remove unapproved prescription cough medications from the market. Chest. 2011 Aug; 140(2):282-4.
-
Kay J. Biosimilars: a regulatory perspective from America. Arthritis Res Ther. 2011 May 12; 13(3):112.
-
Guharoy R. It is time for food and drug administration reform. Arch Intern Med. 2010 Apr 26; 170(8):737.
-
Ellsworth P, Kirshenbaum E. Update on the pharmacologic management of overactive bladder: the present and the future. Urol Nurs. 2010 Jan-Feb; 30(1):29-38, 53.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|